SGO Issues Dec. 4, 2014
Late-breaking abstract submissions open Dec. 9 – Feb. 5
USPSTF seeks comment on pelvic exam screening plan
Cervical cancer screening, HPV vaccine at Annual Meeting
Changes in quality reporting in CY 2015 Final Medicare Rule
Early Career Educational Summit in Chicago Dec. 12-13
Consider a year-end donation to SGO’s Foundation
SGO is accepting late-breaking abstract submissions for the Annual Meeting on Women’s Cancer® Dec. 9, 2014, through Feb 5, 2015. This session will highlight data of the highest scientific impact that has become available since the original 2015 Annual Meeting abstract submission deadline on Sept. 17, 2014. Abstracts already submitted in response to the original Call for Abstracts for the 2015 Annual Meeting are not eligible for resubmission.
The U.S. Preventive Services Task Force (USPSTF, Task Force) today posted for public comment a draft research plan on periodic screening for gynecological conditions with the pelvic examination. The final Research Plan will be used to guide a systematic review of the evidence by researchers at an Evidence-based Practice Center. The resulting Evidence Review will form the basis of the USPSTF Recommendation Statement on this topic. Comments can be submitted from Dec. 4, 2014, through Jan. 7, 2015.
Abstracts on the importance of cervical cancer screening and the HPV vaccine will be presented in Scientific Plenary VI as well as the Seminal Abstract Session during the SGO Annual Meeting on Women’s Cancer in Chicago on March 28-31, 2015. These presentations are particularly important in light of the Centers for Disease Control and Prevention’s recent report on the high number of women who have not been screened for cervical cancer.
Two sessions on Sunday, March 29, will include presentations related to cervical cancer screening and the nonavalent HPV vaccine. During the Seminal Abstract Session Elmar A. Joura, MD, of the Medical University of Vienna, General Hospital (AKH), and Comprehensive Cancer Center in Vienna, Austria will present on the HPV9 vaccine. During Scientific Plenary VI, Warner K. Huh, MD, of University of Alabama at Birmingham will present “Relative prevalence of high risk HPV genotypes in a US population: insights before rollout of the next generation 9-valent”; and Thomas C. Wright, MD, of Columbia University in New York City will present “HPV primary screening incorporating genotyping and p16/Ki-67 dual-stained cytology to determine which HPV positive women would benefit from colposcopy.”
On Nov. 5 the CDC’s Vital Signs Morbidity and Mortality Weekly Report (MMWR) announced that about 8 million women ages 21 to 65 years have not been screened for cervical cancer in the past five years. More than half of new cervical cancer cases occur among women who have never or rarely been screened. The report also found that seven out of 10 women who were not screened had a regular doctor and health insurance.
Other key findings from the MMWR include:
- In 2012, 11.4 percent of women reported they had not been screened for cervical cancer in the past five years; the percentage was larger for women without health insurance (23.1 percent) and for those without a regular health care provider (25.5 percent).
- The percentage of women not screened as recommended was higher among older women (12.6 percent), Asians/Pacific Islanders (19.7 percent), and American Indians/Alaska Natives (16.5 percent).
- From 2007 to 2011, the cervical cancer incidence rate decreased by 1.9 percent per year while the death rate remained stable.
The Centers for Medicare and Medicaid Services (CMS) Final Rule issued on Oct. 31 contains changes to quality reporting initiatives that are associated with Medicare payments, including the Physician Quality Reporting System and the Value-Based Payment Modifier.
SGO provided CMS with comments on these issues in a Sept. 2 letter. The following points summarize the changes:
Physician Quality Reporting System
- The Physician Quality Reporting System is a pay-for-reporting program that beginning in 2015 will have a downward adjustment applied to eligible providers (EPs) that did not successfully report quality data in 2013. For more information, see the CMS Fact Sheet.
- CMS is finalizing a – 2 percent% payment adjustment in 2017 for all those EPs that do not successfully report on nine quality measures during 2015. Measures that members may consider reporting on in 2015 are summarized in this table.
- For EPs and group practices reporting via claims or registry that see at least one Medicare patient in a face-to-face encounter, at least one of the nine must be from the new cross-cutting measure set. (See the “Crosscutting Measures” column in the table above).
Value-Based Payment Modifier
- The Affordable Care Act established a “Value Modifier” that provides for differential payment to a physician or group of physicians under the Medicare Fee Schedule. This modifier is based upon the quality of care furnished as well as the cost of that care during a performance period. The Value Modifier must be applied to all physicians by Jan. 1, 2017. To do that, CMS must use 2015 as the performance period. Read more about the Value Modifier.
- For 2017 payments, CMS finalized an increase in the maximum amount of payment at risk to +/- 4 percent for practice with 10 or more EPs. This adjustment will be based on 2015 quality and cost reporting by physicians.
- For those EPs in practices of nine or less or for solo practitioners, the amount of payment at risk will be +/- 2 percent in 2017. Again, this will be based on data and costs reported in 2015.
By Linda Duska, MD
The 2014 Early Career Educational Summit, to be held Dec. 12-13 in Chicago, is a unique opportunity for gynecologic oncologists interested in mentorship for academic career development. Conducted at the Robert H. Lurie Medical Research Center of Northwestern University, the course is specifically designed to accommodate residents who are interested in gynecologic oncology fellowships, Fellows in gynecologic oncology who are evaluating career opportunities, and Candidate Members who have not yet identified a career niche or who are struggling to maintain work-life balance and academic productivity.
The course contains a number of breakout sessions tailored to participants at different stages in their careers. Our goals are to give attendees the opportunity to:
- Develop a sound understanding of the cooperative group trials that define best practices in gynecologic oncology and understand the scientific methodology that serve as the basis for these landmark studies
- Acquire better skills in negotiating, scientific writing and grantsmanship to bolster their academic careers
- Network with senior members of SGO and establish future mentorship relationships
- Discover alternative opportunities for career development
- Present their research projects and receive feedback
- Learn how to become involved in the Gynecologic Oncology Fellows’ Research Network (GOFRN)
- Explore opportunities to achieve work-life balance
The program consists of lectures and group presentations as well as three concurrent tracks focused on academic development in gynecologic oncology. Key lectures will focus on mentor-mentee relationships, contract negotiation, and academic promotion. Attendees will learn how to find funding sources, write grants, and write more effective scientific papers from experts in the field. The concurrent tracks will allow attendees to choose the focus that interests them the most. These tracks include:
- Update on cooperative group trials, including a session on statistics for clinical research
- Developing careers in comparative effectiveness, translational science/clinical trials, and patient safety/quality outcomes
- Research opportunities in surgical research and quality, including database research.
Attendees may submit their research ideas in abstract form for the purpose of constructive feedback. Additionally, there will be several panel discussions that pertain to not only career development, but other important related topics, like work-life balance.
As the end of 2014 approaches, please consider donating to the Foundation for Gynecologic Oncology to provide resources that help further the subspecialty of gynecologic oncology. Contributions may be deductible as a charitable contribution for federal income tax purposes. (Please consult with your tax advisor.) Contact Jared Cochrum at firstname.lastname@example.org if you have questions or need assistance.